Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 868

Thousands lined up to try out Elon Musk’s brain chip

Elon Musk’s Neuralink is looking for a volunteer for its first clinical trial of a brain implant chip. The trial, which begins next year, has attracted thousands of prospective patients. The ideal candidate must be an adult under 40 with all four limbs paralyzed. The procedure involves inserting electrodes and wires into the brain, with a small computer replacing part of the skull. The computer will collect and analyze brain activity, sending the data wirelessly to a nearby device. Neuralink aims to translate thoughts into computer commands. However, the company has faced criticism for animal testing practices.

Deep-sea sniffer dog? Scientists develop device to detect new molecules

The system shows potential for drug development in delicate environments such as coral reefs.

ACS

To better comprehend this, researchers have presented a proof-of-concept device that “sniffs” seawater, capturing dissolved chemicals for analysis. The underwater device “catches and concentrates dissolved substances generated by sponges or other marine animals while causing no damage to the source or the environment,” said a statement.

Brain implant turns thoughts into speech with up to 84% accuracy

The hope is that people who are unable to speak because of neurological conditions may one day be able to communicate again thanks to this modern technology.

Helping people with motor disorders

“There are many patients who suffer from debilitating motor disorders, like ALS (amyotrophic lateral sclerosis) or locked-in syndrome, that can impair their ability to speak,” said Gregory Cogan, Ph.D., a professor of neurology at Duke University’s School of Medicine and one of the lead researchers involved in the project.

“But the current tools available to allow them to communicate are generally very slow and cumbersome.”

New research identifies a biotechnology approach to improve hybrid breeding of soybean

Soybean (Glycine max) is one of the most economically and societally impactful crops in the world, providing a significant percentage of all protein for animal consumption on a global scale, and playing key roles in oil production, manufacturing, and biofuel applications. In 2022, an estimated 4.3 billion bushels of soybeans were produced in the United States, a decrease of almost 200 million bushels compared to the previous year.

To keep up with the growing demand for soy-based animal feed, the USDA projects acreage will increase by 19.6% by 2032. Hybrid breeding in soybean has the potential to increase the productivity of one of the most planted and consumed in the Americas, yet it has remained largely unexplored.

New research by scientists at the Donald Danforth Plant Science Center and Cornell University provides a key enabling technology to produce obligate outcrossing in soybean. The newly published study, “Introduction of barnase/barstar in soybean produces a rescuable male sterility system for hybrid breeding” in the Plant Biotechnology Journal, has revealed that obligate outcrossing with the Barnase/Barstar lines provides a new resource that can be used to amplify hybrid seed sets, enabling large-scale trials for heterosis in this major crop.

Artificial bladders shine light on pathogens that cause urinary tract infections

Research published in Science Advances is the first to use a sophisticated human tissue model to explore the interaction between host and pathogen for six common species that cause urinary tract infections. The findings suggest that the “one size fits all” approach to diagnosis and treatment currently used in most health care systems is inadequate.

Urinary tract (UTI) is a growing problem, with around 400 million global cases per year and an estimated 250,000 UTI-related deaths associated with antimicrobial resistance (AMR). Although UTI is often perceived as a simple bacterial infection, 25–30% of UTIs recur within six months despite antibiotic therapy for reasons that are poorly understood.

A condition that primarily affects women, UTI has been historically understudied and underfunded, with no improved anti-infective treatments introduced since Alexander Fleming discovered antibiotics nearly a century ago. Diagnosis primarily rests on the midstream urine culture method (dipstick test), an early 20th century technique that is known to miss many infections.

Boosting beta cells to treat type 2 diabetes

Researchers at Weill Cornell Medicine have uncovered a novel route to stimulate the growth of healthy insulin-producing pancreatic beta cells in a preclinical model of diabetes. The findings hold promise for future therapeutics that will improve the lives of individuals with type 2 diabetes—a condition that affects more than half a billion people worldwide.

This study, published in the Journal of Clinical Investigation on Sept. 15, demonstrated that activating a pathway to promote not only expanded the population of insulin-producing cells, but surprisingly, it also enhanced the cells’ function.

“That’s reassuring because there is a long-standing belief in the field that proliferation can lead to ‘de-differentiation’ and a loss of cell function,” said study senior author Dr. Laura Alonso, chief of the division of endocrinology, and metabolism, director of the Weill Center for Metabolic Health, and the E. Hugh Luckey Distinguished Professor in Medicine at Weill Cornell Medicine. “Our result flies in the face of that dogma and suggests if we can find a way to trigger replication of the in the body, we won’t impair their ability to produce and secrete insulin.”

/* */